Senti Biosciences (SNTI) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to SENTI-202 for relapsed/refractory hematologic malignancies including AML.
SENTI-202 is a first-in-class off-the-shelf Logic Gated CD33 OR FLT3 NOT EMCN CAR NK cell therapy product candidate designed to selectively target and eliminate CD33 and/or FLT3-expressing hematologic malignancies.
The FDA Office of Orphan Products Development awards Orphan Drug Designation to products with potential to treat rare diseases affecting fewer than 200,000 people in the United States.
